Literature DB >> 6743476

Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.

W Kirch, H Spahn, N R Kitteringham, H J Hutt, E Mutschler, E E Ohnhaus.   

Abstract

Neither the kinetics of the hydrophilic beta-adrenoceptor blocker atenolol nor those of the lipophilic metoprolol were influenced by the concurrent administration of amitriptyline. Compared with placebo, chronic administration (14 days) of atenolol and metoprolol (each as monotherapy) did not significantly reduce oxidative liver metabolism as measured by antipyrine half-life and by 6-beta-hydroxycortisol excretion. Compared with atenolol and metoprolol monotherapy, chronic administration of amitriptyline concurrently with each of the beta-adrenoceptor blockers produced an insignificant decrease (circa 10-20%) in antipyrine half-life and 6-beta-hydroxycortisol excretion. Amitriptyline appears therefore to have little enzyme-inducing activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743476      PMCID: PMC1463264          DOI: 10.1111/j.1365-2125.1984.tb02430.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin.

Authors:  E E Ohnhaus; B Kirchhof; E Peheim
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

3.  Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms.

Authors:  M Schäfer; E Mutschler
Journal:  J Chromatogr       Date:  1979-02-01

4.  Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms.

Authors:  M Schäfer; E Mutschler
Journal:  J Chromatogr       Date:  1979-10-11

5.  Pharmacokinetics of atenolol in relation to renal function.

Authors:  W Kirch; H Köhler; E Mutschler; M Schäfer
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

6.  Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

Authors:  N D Bax; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

7.  Atenolol kinetics in renal failure.

Authors:  J McAinsh; B F Holmes; S Smith; D Hood; D Warren
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

8.  The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.

Authors:  T K Daneshmend; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system.

Authors:  N C Henningsen; I Mattiasson
Journal:  Acta Med Scand       Date:  1979

10.  Interaction of atenolol with furosemide and calcium and aluminum salts.

Authors:  W Kirch; M Schäfer-Korting; T Axthelm; H Köhler; E Mutschler
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

View more
  4 in total

1.  Lack of effect of atenolol on the pharmacokinetics of theophylline.

Authors:  L A Cerasa; J S Bertino; E A Ludwig; M Savliwala; E Middleton; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 2.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

3.  Lack of effect of atenolol and nadolol on the metabolism of theophylline.

Authors:  C M Corsi; A N Nafziger; J A Pieper; J S Bertino
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 4.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.